Bridge Biotherapeutics

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015.

[Bridge Biotherapeutics @BridgeBiorx]

@BioscienceLA @djwhelan Thanks for having us!

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its #IPF Franchise: Read more at https://t.co/CYJWaKfQUJ #GPCR19_agonist

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics Presented the #Preclinical Data of BBT-207 at the #AACR Annual Meeting 2022: Read more at https://t.co/X7utYnVb0w #EGFR_TKI

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the #AACR 2022 Annual Meeting https://t.co/R8ejAMYgOS #NSCLC #EGFRTKI

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics https://t.co/AAmuMIxN7o

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics attends and presents our business at #BioCenturyBayHelix #ChinaHealthcareSummit from Nov 16 to 19, 2021 online. More info available at: https://t.co/qhDOZY7uiW
#ChinaSummit21

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China https://t.co/GOl3TDKIaK

#ulcerativecolitis #uc #궤양성대장염

[Bridge Biotherapeutics @BridgeBiorx]

We are pleased to announce that the pre-clinical data of BBT-176, our #NSCLC candidate via an ePoster at the European Society for Medical Oncology (ESMO) Congress 2021. Read more at: https://t.co/UZWJg62IY9

#ESMO #EGFR #C797S

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics Integrates @CDDVault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management
https://t.co/iuJtwE2Jol

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis: Rectal Delivery of Drug to the Target Site https://t.co/Qf2Y6qznDz
#ulcerativecolitis #clinicaltrials #biotech #Pellino

[Bridge Biotherapeutics @BridgeBiorx]

Korea Spotlight: Shaking off BI setback, Bridge expands scope of BD, advances in-house therapies  https://t.co/Lh9jLh0JQK

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S https://t.co/X4yPyFdyhh #NSCLC #C797S #oncology #lungcancer

[Bridge Biotherapeutics @BridgeBiorx]

11월 한 달간의 브릿지바이오 소식을 전해 드립니다. https://t.co/a36x9hR1Zw
▶️ 2020년 3분기 실적보고 및 기업설명회 ▶️ 해외 기관 대상 IR ▶️ BBT-877 독점권리 반환 ▶️ 주요 파이프라인 개발 진행 현황 업데이트 #바이오텍 #biotech #bridge_science_and_patients

[Bridge Biotherapeutics @BridgeBiorx]

Please refer to the press release on the termination of Bridge Biotherapeutics's collaboration and license agreement with Boehringer Ingelheim. https://t.co/TbCMVgjbYM

[Bridge Biotherapeutics @BridgeBiorx]

10월 한 달간의 브릿지바이오 소식을 전해 드립니다. https://t.co/nFX3ZBf9wk
✅ 코스닥 온라인 글로벌 IR 참석 ✅ 주요 파이프라인 개발 진행 현황 업데이트 ▶️ #뉴스레터 구독은 여기서: https://t.co/FzFiON6hKz #바이오텍 #biotech #bridge_science_and_patients

[Bridge Biotherapeutics @BridgeBiorx]

Highly excited to share an article, which highlights the promise of the Swiss #biotech industry and the recent collaborations between Swiss and Korean biotechs, including Bridge Biotherapeutics. [The Korea Herald Weekender] Korean bio taps Switzerland https://t.co/4Jz8tpxIfB

[Bridge Biotherapeutics @BridgeBiorx]

@PlexusVentures @MktsInsider @EidosTx Congrats! I’m afraid but the account @BridgeBiorx is on behalf of different biotech headquartered in Seoul, South Korea..!

[Bridge Biotherapeutics @BridgeBiorx]

9월 브릿지바이오 소식을 전해드립니다. https://t.co/fuWt5nm7Bf ✅ BBT-401 개발현황 업데이트 ✅ 무상증자 실시 결의 ✅ 창립 5주년 감사 인사 #뉴스레터 구독은 여기서! https://t.co/fTDmMZaVix #NRDO #바이오텍 #biotech

[Bridge Biotherapeutics @BridgeBiorx]

Bridge Biotherapeutics announced detailed plans for the Phase 2a study of BBT-401, a Pellino-1 inhibitor for ulcerative colitis. https://t.co/M9raRoi7U6

[Bridge Biotherapeutics @BridgeBiorx]

Glad to celebrate the 5th anniversary of Bridge Biotherapeutics!